Zoetis Inc (ZTS)
175.18
-6.77
(-3.72%)
USD |
NYSE |
Nov 04, 16:00
175.25
+0.07
(+0.04%)
After-Hours: 20:00
Zoetis Enterprise Value: 87.42B for Nov. 1, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 01, 2024 | 87.42B |
| October 31, 2024 | 85.98B |
| October 30, 2024 | 87.77B |
| October 29, 2024 | 87.11B |
| October 28, 2024 | 87.78B |
| October 25, 2024 | 86.54B |
| October 24, 2024 | 87.21B |
| October 23, 2024 | 90.61B |
| October 22, 2024 | 90.84B |
| October 21, 2024 | 90.81B |
| October 18, 2024 | 92.55B |
| October 17, 2024 | 91.52B |
| October 16, 2024 | 93.08B |
| October 15, 2024 | 92.15B |
| October 14, 2024 | 92.26B |
| October 11, 2024 | 91.10B |
| October 10, 2024 | 91.19B |
| October 09, 2024 | 91.14B |
| October 08, 2024 | 89.87B |
| October 07, 2024 | 89.83B |
| October 04, 2024 | 91.08B |
| October 03, 2024 | 91.51B |
| October 02, 2024 | 92.18B |
| October 01, 2024 | 93.07B |
| September 30, 2024 | 93.50B |
| Date | Value |
|---|---|
| September 27, 2024 | 93.24B |
| September 26, 2024 | 93.27B |
| September 25, 2024 | 91.76B |
| September 24, 2024 | 92.74B |
| September 23, 2024 | 92.69B |
| September 20, 2024 | 92.26B |
| September 19, 2024 | 92.53B |
| September 18, 2024 | 94.00B |
| September 17, 2024 | 93.65B |
| September 16, 2024 | 92.99B |
| September 13, 2024 | 91.56B |
| September 12, 2024 | 91.39B |
| September 11, 2024 | 91.06B |
| September 10, 2024 | 91.68B |
| September 09, 2024 | 91.85B |
| September 06, 2024 | 90.71B |
| September 05, 2024 | 89.52B |
| September 04, 2024 | 89.85B |
| September 03, 2024 | 88.15B |
| August 30, 2024 | 88.11B |
| August 29, 2024 | 87.84B |
| August 28, 2024 | 87.85B |
| August 27, 2024 | 87.48B |
| August 26, 2024 | 87.24B |
| August 23, 2024 | 86.94B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
48.55B
Minimum
Mar 23 2020
120.20B
Maximum
Dec 29 2021
83.63B
Average
83.08B
Median
Enterprise Value Benchmarks
| Pfizer Inc | 221.03B |
| Alnylam Pharmaceuticals Inc | 33.57B |
| Biomarin Pharmaceutical Inc | 12.36B |
| Corcept Therapeutics Inc | 4.609B |
| Ionis Pharmaceuticals Inc | 5.311B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 624.00M |
| Revenue (Quarterly) | 2.361B |
| Total Expenses (Quarterly) | 1.455B |
| EPS Diluted (Quarterly) | 1.37 |
| Gross Profit Margin (Quarterly) | 71.71% |
| Profit Margin (Quarterly) | 26.43% |
| Earnings Yield | 2.92% |
| Operating Earnings Yield | 4.00% |
| Normalized Earnings Yield | 3.109 |